170 related articles for article (PubMed ID: 35850480)
1. Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity.
Dengler DG; Sun Q; Harikumar KG; Miller LJ; Sergienko EA
SLAS Discov; 2022 Oct; 27(7):384-394. PubMed ID: 35850480
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.
Harikumar KG; Coudrat T; Desai AJ; Dong M; Dengler DG; Furness SGB; Christopoulos A; Wootten D; Sergienko EA; Sexton PM; Miller LJ
Front Endocrinol (Lausanne); 2021; 12():789957. PubMed ID: 34950108
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.
Miller LJ; Desai AJ
Trends Endocrinol Metab; 2016 Sep; 27(9):609-619. PubMed ID: 27156041
[TBL] [Abstract][Full Text] [Related]
4. Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.
Desai AJ; Henke BR; Miller LJ
Bioorg Med Chem Lett; 2015 May; 25(9):1849-55. PubMed ID: 25862198
[TBL] [Abstract][Full Text] [Related]
5. Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor.
Desai AJ; Mechin I; Nagarajan K; Valant C; Wootten D; Lam PCH; Orry A; Abagyan R; Nair A; Sexton PM; Christopoulos A; Miller LJ
Mol Pharmacol; 2019 Mar; 95(3):245-259. PubMed ID: 30591538
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype.
Desai AJ; Dong M; Langlais BT; Dueck AC; Miller LJ
Am J Clin Nutr; 2017 Aug; 106(2):447-456. PubMed ID: 28592602
[No Abstract] [Full Text] [Related]
7. Mechanism of Action and Structure-Activity Relationships of Tetracyclic Small Molecules Acting as Universal Positive Allosteric Modulators of the Cholecystokinin Receptor.
Dengler DG; Harikumar KG; Yen A; Sergienko EA; Miller LJ
Membranes (Basel); 2023 Jan; 13(2):. PubMed ID: 36837653
[TBL] [Abstract][Full Text] [Related]
8. Roles of Cholecystokinin in the Nutritional Continuum. Physiology and Potential Therapeutics.
Miller LJ; Harikumar KG; Wootten D; Sexton PM
Front Endocrinol (Lausanne); 2021; 12():684656. PubMed ID: 34149622
[TBL] [Abstract][Full Text] [Related]
9. A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.
Desai AJ; Harikumar KG; Miller LJ
J Biol Chem; 2014 Jun; 289(26):18314-26. PubMed ID: 24825903
[TBL] [Abstract][Full Text] [Related]
10. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
[TBL] [Abstract][Full Text] [Related]
11. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
[TBL] [Abstract][Full Text] [Related]
12. Development of a Testing Funnel for Identification of Small-Molecule Modulators Targeting Secretin Receptors.
Dengler DG; Sun Q; Holleran J; Pollari S; Beutel J; Brown BT; Shinoki Iwaya A; Ardecky R; Harikumar KG; Miller LJ; Sergienko EA
SLAS Discov; 2021 Jan; 26(1):1-16. PubMed ID: 32749201
[TBL] [Abstract][Full Text] [Related]
13. Permanent Photodynamic Cholecystokinin 1 Receptor Activation: Dimer-to-Monomer Conversion.
Jiang WY; Li Y; Li ZY; Cui ZJ
Cell Mol Neurobiol; 2018 Aug; 38(6):1283-1292. PubMed ID: 29869099
[TBL] [Abstract][Full Text] [Related]
14. Functional compensation between cholecystokinin-1 and -2 receptors in murine paraventricular nucleus neurons.
Mohammad S; Ozaki T; Takeuchi K; Unno K; Yamoto K; Morioka E; Takiguchi S; Ikeda M
J Biol Chem; 2012 Nov; 287(47):39391-401. PubMed ID: 23038256
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
Desai AJ; Lam PC; Orry A; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
J Med Chem; 2015 Dec; 58(24):9562-77. PubMed ID: 26654202
[TBL] [Abstract][Full Text] [Related]
16. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.
Berna MJ; Tapia JA; Sancho V; Jensen RT
Curr Opin Pharmacol; 2007 Dec; 7(6):583-92. PubMed ID: 17997137
[TBL] [Abstract][Full Text] [Related]
17. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.
Burford NT; Clark MJ; Wehrman TS; Gerritz SW; Banks M; O'Connell J; Traynor JR; Alt A
Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10830-5. PubMed ID: 23754417
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.
Desai AJ; Dong M; Harikumar KG; Miller LJ
Int J Obes Suppl; 2016 Dec; 6(Suppl 1):S22-S27. PubMed ID: 28685026
[TBL] [Abstract][Full Text] [Related]
19. Genetic, pharmacological and functional analysis of cholecystokinin-1 and cholecystokinin-2 receptor polymorphism in type 2 diabetes and obese patients.
Marchal-Victorion S; Vionnet N; Escrieut C; Dematos F; Dina C; Dufresne M; Vaysse N; Pradayrol L; Froguel P; Fourmy D
Pharmacogenetics; 2002 Jan; 12(1):23-30. PubMed ID: 11773861
[TBL] [Abstract][Full Text] [Related]
20. Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy.
Roth E; Benoit S; Quentin B; Lam B; Will S; Ma M; Heeley N; Darwish T; Shrestha Y; Gribble F; Reimann F; Pshenichnaya I; Yeo G; Baker DJ; Trevaskis JL; Blouet C
Mol Metab; 2021 Jan; 43():101118. PubMed ID: 33221554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
